GENEVA—Toxicities from targeted agents used in lung cancer differ from those encountered with other drugs but can be managed successfully if recognized early and treated. At the European Lung Cancer Conference, Silvia Novello MD, PhD, an Assistant Professor of Respiratory Medicine at the Department of Clinical and Biological Sciences of the University of Turin, Italy, told Oncology Times reporter Peter Goodwin how side effects—including diarrhea, metabolic disturbances and electrolyte imbalances—to treatments targeting EGFR and immune checkpoints have been managed in her clinic, demonstrating that careful planning and vigilance can help deliver new-generation drug regimens on-dose on-time to achieve significant improvements in outcomes.
You may also like...
Video: Txt2Stop: Text Messaging Doubled Smoking Quit Rates 5 Jul, 2011 Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015 First effective treatment for “orphan disease’: Anti I/L 6 antibody brings remissions in Multicentric Castleman’s Disease 21 Jan, 2014 Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time 24 Mar, 2015
- Previous story No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed
- Next story Three Drug Regimen Best for Squamous Non Small Cell Lung Cancer—Even in Older Patients
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014